Eton Pharmaceutcials Inc ETON

$55.36 +3.38 (6.50%)

Valuation

Market cap
1,485,744,000
Revenue TTM
$79,950,000
Net income TTM
$-4,600,000
PE ratio
135.50
Forward PE
45.77
Profit margin
-5.75%
Debt to equity
0.60

Trading

Volume
750,000
Avg volume
618,220
Day's range
$52.00 – $56.00
Shares out
28,583,000
Stochastic %K
56%
Beta
0.90
Analysts
Strong Sell
Price target
$64.10

Price

Company profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate syn...

Show more

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
847 787 7361
Website
https://www.etonpharma.com
Address
21925 W. Field Parkway, Suite 235, Deer Park, United States

Latest news

Stocktwits

CharlieeMungerTWITS Oct 3, 12:13 AM
$CELC If CELC had collapsed from $100 to $72 while XBI was ripping higher and LABD was collapsing, I’d be considerably more concerned. That would suggest CELC-specific selling. But that’s not what’s up… Instead, you’ve had a pretty nasty risk-off environment for biotech and smaller-cap equities generally. The broader market has also become unusually narrow. LABD up like 30%. The WSJ reports that since September nearly 80% of S&P 500 stocks have declined, while AI-related mega-caps have masked much of the weakness in the headline indexes. Small caps have been particularly weak. $ETON $CORT
0 replies
Tennis_4567 Oct 1, 9:54 AM
$ETON giant gap waiting to be filled at $43
2 replies
RBuskey106 Sep 30, 8:04 PM
$ETON Come back to the $40S
0 replies
investpapaya Sep 30, 6:53 PM
$ETON ... major profit taking?
1 replies
InItToWinIt100 Sep 30, 6:51 PM
$ETON More downside ahead. Gap fill below into $43's. https://www.trade-ideas.com/share.php?code=ZcC2xp53oWpXzXVSTjURpa8sNVqMiWQq
0 replies
Arcides Sep 30, 6:43 PM
$ETON and there is the selling...
0 replies
Dbarnyard Sep 30, 5:49 PM
$ETON Is this just insiders dumping or do we have some sort of negative news incoming, ie. regulatory, that isn't yet publicly known? I guess we'll know in the next few days...
0 replies
DannyMac56 Sep 30, 5:49 PM
$ETON WHAT ???
0 replies